Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 230
Summary
- Conditions
- Sepsis
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The main goal of this project is to measure kidney filtration function at day 14 or the day of discharge from hospital (whichever occurs first), in order to determine the presence and magnitude of persistent kidney dysfunction after sepsis episode and to longitudinally assess further decline of kidn...
The main goal of this project is to measure kidney filtration function at day 14 or the day of discharge from hospital (whichever occurs first), in order to determine the presence and magnitude of persistent kidney dysfunction after sepsis episode and to longitudinally assess further decline of kidney function at one year follow-up. The measure of the glomerular filtration rate (GRF) in patients with chronic critical illness and controls (sepsis patients discharged from ICU before day 14) will be used to determine to what degree of kidney dysfunction contributes to decreased survival and increase in chronic kidney disease at year one after sepsis onset. One and/or all of the three ways for GFR assessment will be used, both at approximately day 14 or approximately at the day of discharge from the ICU and at the one year follow up : Determine clearance of Iohexol from blood after Iohexol injection and/or Determine apperance of Iohexol in urine after Iohexol injection (this would be the same injection as in one, and would not require two injections) and/or A timed urine collection to determine clearance of urea and creatinine and/or Estimated GFR using calculations with serum creatinine and cystatin C, This will provide an opportunity to validate the different measurements.
Tracking Information
- NCT #
- NCT02276066
- Collaborators
- National Institutes of Health (NIH)
- National Institute of General Medical Sciences (NIGMS)
- Investigators
- Principal Investigator: Mark Segal, M.D. University of Florida